Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2021

View Archived Issues

KRAS just wants to help: Pancreatic KRAS mutations may be protection gone bad

CNGA1 behind retinal degeneration, murine model shows

Guanylate cyclase C agonist IW-3300 shows promise for treating visceral pain

Mitokinin discloses PINK1 activators

Bahcesehir Universitesi presents Hdm2 inhibitors

Achillion Pharmaceuticals identifies new complement factor D inhibitors

UCL Business describes new CRP inhibitors

Nanjing Sanhome Pharmaceutical divulges anti-CD47/anti-PD-L1 antibodies

Novel potent TGR5 agonist shows antidiabetic effects in TGR5(H88Y) mutant mice

VU-6028418 reverses cataleptic behavior in rat models

Endeavor BioMedicines licenses rights to ULK1/2 inhibitor for LKB1- and RAS-mutated cancers

Targeting PANX1/IL-33 axis decreases MRSA infection-induced liver damage

RARG rs2229774 genetic variant identifies cardioprotective therapy

Bantam completes seed funding to advance BTM-3566 toward the clinic

Tarveda and SciClone enter license agreement for preclinical PI3K miniature drug conjugates

Targeting RON short form suppresses breast cancer metastasis through subverted immunosuppression

Clarus licenses rights to McGill technology to treat conditions associated with CoQ10 deficiencies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...